John W. Walsh Alpha-1 Home Infusion Act of 2025
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
John W. Walsh Alpha-1 Home Infusion Act of 2025
This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 2343: John W. Walsh Alpha-1 Home Infusion Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-HR-2343/
"H.R. 2343: John W. Walsh Alpha-1 Home Infusion Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-2343/.
H.R. 2343, 119th Cong. (2026), https://openamerica.io/bill/119-HR-2343/.
[H.R. 2343: John W. Walsh Alpha-1 Home Infusion Act of 2025](https://openamerica.io/bill/119-HR-2343/)